Structure Therapeutics Inc.
Close on Oct 19, 2026
- Market cap
- $4.80B
- P/E (TTM)
- –
- Dividend yield
- –
About Structure Therapeutics
Pharmaceutical Preparations, SIC 2834
Structure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral small molecule therapeutics for chronic diseases with unmet medical need. Utilizing a structure-based drug discovery platform and computational chemistry, the enterprise targets G-protein coupled receptors across metabolic, cardiovascular, and pulmonary conditions. Its lead product candidate is aleniglipron (GSBR-1290), an oral GLP-1 receptor agonist in clinical trials for obesity and overweight management. The company is also advancing oral small molecule amylin receptor agonists, including ACCG-2671 and ACCG-3535, alongside discovery-stage programs targeting GIP, glucagon, and APJ receptors for use as monotherapies or fixed-dose combinations for individuals living with metabolic and chronic disorders.
The company maintains a global presence with clinical trials conducted across multiple sites in the United States and Japan. Its manufacturing infrastructure provides a production capacity of 6,000 tons per year of aleniglipron. The provided text does not state the company's specific headquarters location.
Summary of the business section of Structure Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Structure Therapeutics Inc.
- Headquarters
- South San Francisco, CA
- Address
- 601 Gateway Blvd Suite 900 94080
- Phone
- (650) 457-1978
- Employees
- 220, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- E9
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Mateo, California
Stock & identifiers
- Ticker
- GPCR
- Exchange
- Nasdaq
- IPO date
- Feb 6, 2023
- Shares outstanding
- 214M, Jul 31, 2026
- Public float
- $834.90M, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1888886
- CUSIP
- 86366E106
- ISIN
- US86366E1064
- EIN
- 98-1480821
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Raymond C. Stevens | CHIEF EXECUTIVE OFFICER, Director | 2,956,179 |
| Crespo Blas Coll | CHIEF MEDICAL OFFICER | 258,228 |
| Xichen Lin | CHIEF SCIENTIFIC OFFICER | 228,960 |
| John Joseph Berrios | Chief Commercial Officer | 140,766 |
| Matthew Lang | COO & GC | 184,614 |
| Jun Yoon | CHIEF FINANCIAL OFFICER | 2,956,242 |
| Yingli Ma | CHIEF TECHNOLOGY OFFICER | 139,917 |
| Ashley Hall | Chief Development Officer | 155,187 |
| Eric Dobmeier | Director | – |
| Angus C. Russell | Director | – |
| Ted W. Love | Director | – |
| Daniel G. Welch | Director | 123,508 |
| Sharon Tetlow | Director | – |
| Joanne Waldstreicher | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Raymond Stevens, Ph.D. | $8.43M | $36.23M | $3.05M | $268 | $135 |
| FY2024 Raymond Stevens, Ph.D. | $5.74M | $1.74M | $3.57M | $104 | $101 |
| FY2023 Raymond Stevens, Ph.D. | $7.39M | $22.06M | $2.17M | $157 | $102 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 220 full-time employees, 75 of whom have a Ph.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 14, 2023 | Late filing | Notification of late filing |
| Jun 5, 2023 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Feb 6, 2023 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 30, 2023 | Listing | Registration of securities on an exchange (Form 8-A) |
| May 13, 2022 | Name change | Name changed from ShouTi Inc. to Structure Therapeutics Inc. |